webinar register page

What’s new in Pharmacogenomics (PGx) in Psychiatry: Emerging research evidence and considerations for clinical utility, implementation, and counseling.
Learning Objective #1
Examine the evidence for using PGx testing to guide depression treatment as compared to treatment as usual.
Learning Objective #2
Compare patient and providers’ perceptions of PGx testing for depression and its clinical implementation within a public healthcare system.

Learning Objective #3
Summarize patient preferences and needs for accessing PGx testing for depression, and the resulting considerations for pre- and post-test counseling.

20 minutes for the 1st presentation on the meta analysis of data on the utility of pharmacogenomic testing for depression. (Title: “Evaluating treatment outcomes in pharmacogenomic-guided care for major depression: a rapid review and meta-analysis”)
Will PGx help improve outcomes for individuals with depression (e.g., supporting remission and reducing adverse medication effects?)
Goal: increase GC awareness of the current research on the utility of PGx testing to support depression treatment specifically through meta-analysis of randomized control trials and discuss where more research is needed.

20 minutes for presentation on qualitative research (“Pharmacogenomic testing for major depression: a qualitative study of the perceptions of people with lived experience and professional stakeholders”) looking at how PGx may be helpful and best delivered from the perspective of individuals with lived experience of depression.
Goal to help inform GC awareness and understanding of what would be helpful to include in a PGx genetic counseling session as informed by the lived experience of individuals with depression.
Another consideration is what is within the scope of a GC to discuss in a PGx counseling session with a patient/client. What other health care providers need to be consulted/included to meet patient/client needs?

20 minutes panel discussion (we plan to review questions submitted

May 25, 2022 01:00 PM in Central Time (US and Canada)

* Required information